BigSur Wealth Management LLC Increases Stake in Eli Lilly and Company $LLY

BigSur Wealth Management LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 266.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,200 shares of the company’s stock after buying an additional 1,600 shares during the period. BigSur Wealth Management LLC’s holdings in Eli Lilly and Company were worth $1,715,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in LLY. Palumbo Wealth Management LLC raised its holdings in Eli Lilly and Company by 99.8% in the 2nd quarter. Palumbo Wealth Management LLC now owns 993 shares of the company’s stock worth $774,000 after acquiring an additional 496 shares during the last quarter. Xcel Wealth Management LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth $326,000. DSG Capital Advisors LLC raised its stake in shares of Eli Lilly and Company by 4.1% in the second quarter. DSG Capital Advisors LLC now owns 30,455 shares of the company’s stock worth $23,741,000 after purchasing an additional 1,193 shares during the last quarter. Cora Capital Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 12.6% during the second quarter. Cora Capital Advisors LLC now owns 1,163 shares of the company’s stock valued at $907,000 after purchasing an additional 130 shares in the last quarter. Finally, Affinity Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 1.6% during the second quarter. Affinity Wealth Management LLC now owns 13,029 shares of the company’s stock valued at $10,157,000 after buying an additional 206 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on LLY shares. Berenberg Bank reaffirmed a “hold” rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Morgan Stanley reiterated an “overweight” rating and set a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Deutsche Bank Aktiengesellschaft lowered their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Finally, Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $939.61.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $742.51 on Thursday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a 50-day simple moving average of $736.05 and a two-hundred day simple moving average of $768.68. The firm has a market capitalization of $702.75 billion, a PE ratio of 48.53, a P/E/G ratio of 1.04 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $939.30.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the company posted $3.92 EPS. The firm’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Buying and Selling

In other Eli Lilly and Company news, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Gabrielle Sulzberger acquired 117 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 in the last three months. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.